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Abstract
Background: Small airways are considered the major site of airflow limitation in COPD. Impulse oscillometry (IOS) is
a forced oscillation technique, which provides passive measurement of lung mechanics. It can differentiate small
airway from large airway obstruction and is more sensitive than spirometry for peripheral airway disease. In this
study the efficacy of the combination of Indacaterol/Glycopirronium (IND/GLY) versus Tiotropium on airway
resistance (R5, R20, R5–20), lung reactance (X) and resonant frequency in moderate to severe COPD patients has
been evaluated. We also evaluated inspiratory capacity (IC), forced expiratory volume in 1 s (FEV1), forced vital
capacity (FVC), exacerbation rate and quality of life.
Methods: Forty patients were monitored with forced oscillation technique and spirometry. Patients were
randomized in 2 groups: 20 received fixed dose once daily Indacaterol/Glycopyrronium (Group A) and 20 received
single Tiotropium (Group B).
The oscillometry parameters were the measure of resistance in the airways at 5 Hz (R5), at 20 Hz (R20) and the lung
reactance (X).
Results: There was a statistically significant difference between pre-dosing at V1 and at follow up visits in R5, R20
and X values in patients receiving dual bronchodilation but not in control group. Pre-dosing IC value at follow up
visits in patients receiving dual bronchodilation had a statistical significant variation.
Conclusions: The “new” bronchodilator combination LABA/LAMA significantly reduces bronchial obstruction in
small airways too. The oscillometry demonstrated greater sensitivity compared with spirometry for monitoring
outcome measures of airway obstruction and the effect of long-term therapy.
Keywords: COPD, Impulse oscillometry lung function, Pulmonary function test, Small airway obstruction
Background
Chronic Obstructive Pulmonary Disease (COPD) is a
common, preventable and treatable disease characterized
by persistent respiratory symptoms and airflow limitation
due to airway and/or alveolar abnormalities [1]. At
present, the diagnosis and staging of COPD is difficult,
as spirometry alone is unable to evaluate the severity of
this disease because early pathological changes in COPD
are localized within small airways with diameter < 2 mm
to 4 mm. Static lung hyperinflation is often one of the sig-
nificant challenges in patients with COPD. It is charac-
terised by a decrease in the elastic recoil of the lungs with
a premature closure of small airways leading to air trap-
ping [2]. The impact on lung function parameters is
expressed by an increase in functional residual capacity
(FRC) and a progressive decrease in inspiratory reserve
volume and inspiratory capacity (IC) [3]. Spirometry in-
volves a forced expiratory manoeuvre, which may not be
the ideal test to detect subtle improvements in airway
calibre in COPD due to effort-dependent small airways
closure. Furthermore, FEV1 mainly measures the degree
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of obstruction in large and intermediate airways [4, 5]
while COPD is a disease mainly residing in the peripheral
airways. Other lung function assessments are necessary to
describe the disease pattern. Impulse oscillometry (IOS) is
easier to perform in COPD patients [6]. It is an effort - in-
dependent test performed during normal quiet breathing,
thereby obviating expiratory small airways closure and
measuring the frequency - dependent airway resistance
and reactance (X) [7].
Tiotropium is a long-acting muscarinic antagonist, with
a 24-h persistent bronchodilator effect thus given once
daily [8]. Actually, according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) guidelines,
the bronchodilation therapy (anticholinergic and β2-ago-
nists) is central to the pharmacological interventions for
COPD. We can use single or double (combination of β2
agonist and antimuscarinic drug) bronchodilator agent as
maintenance therapy for patients with mild to very severe
COPD, depending on symptoms severity and exacerbation
frequency.
Combining bronchodilators with different mechanism
and duration of action may increase the degree of bron-
chodilation with a lower risk of side-effects compared to
increasing dosage of a single bronchodilator [1, 9]. Fixed
dose combinations (FDCs) provide potent bronchodilation
versus single agents, with some advantage in terms of
convenience and simplicity compared with combinations
administered via separate inhalers.
There is evidence from prospective clinical studies in-
dicating greater improvement in lung function with
LABA/LAMA combination therapy compared with
increasing the dose of a single bronchodilator in patients
with moderate-to-severe COPD [9]. The once-daily
fixed-dose combination of indacaterol (IND, a LABA)
with glycopyrronium (GLY, a LAMA) 110/50 μg com-
bines these two bronchodilators in a single inhaler and
is approved for maintenance treatment of patients with
moderate to very severe COPD.
However, there are limited data on the effects of the
combination IND/GLY on small airways in patients
with COPD.
In this study we evaluated the efficacy of the com-
bination of IND/GLY versus Tiotropium alone on IOS
parameters in patients with moderate to severe
COPD. We also evaluated lung function including in-
spiratory capacity (IC), as well as exacerbation rate
and quality of life.
Methods
Inclusion criteria
Male or female aged ≥40 years who had received a diagno-
sis of moderate-to- severe COPD according to Global Ini-
tiative for Chronic Obstructive Lung Disease guidelines
[10], and had a post-bronchodilator forced expiratory
volume in 1 s (FEV1) of ≥30% to <80% of predicted nor-
mal, [10] and a post-bronchodilator FEV1 to forced vital
capacity (FVC) ratio of <0.7 smoking history >10 pack/
years; and >1 exacerbation in the last 12 months.
Exclusion criteria
Atopy; exacerbation within 4 weeks before screening,
upper respiratory tract infection within 4 weeks be-
fore screening; other respiratory conditions such as
haemoptysis, asthma, Idiopathic pulmonary fibrosis
(IPF), lung cancer, recent history of rib fracture and
pneumothorax.
Subjects
Patient demographics and other baseline characteristics
are shown in Table 1.
All patients attended the clinical laboratory for 4
study visits (every three months), from January 2015
to July 2016.
All subjects gave their written informed consent and
the study was approved by Ethics Committee (SUN-AO
Dei Colli, Naples, Italy).
Study design
This was a 52-week randomized, open-label, parallel group
study carried out in accordance with the Declaration of
Helsinki.
Table 1 Characteristics of patients
Mean (SD)
IND/GLY
Mean (SD)
Tiotropium
Mean
Total
Patients (M) 20 (17) 20 (18)
Age 70.4 (7.83) 72.01 (6.79) 71.09
BMI 27.85 (5.54) 27.40 (6.02) 27.64
Years from COPD
diagnosis
7.45 (5.5) 8.3 (4.6) 7.81
Smokers/Former
smokers
3/17 1/14 4/31
GOLD Stage B 8 7 15
C 4 3 7
D 8 5 13
FEV1 L 1.29 (0.33) 1.27 (0.39) 1.28
% 52.26 (9.04) 52.13 (11.33) 52.20
FVC L 2.21 (0.52) 2.18 (0.54) 2.20
% 70.2 (9.4) 68.2 (9.5) 69.92
IT % 52.6 (9.4) 56.2 (9.5) 54.5
IC L 1.63 (0.59) 1.64 (0.61) 1.636
% 68.61 (19.87) 69.16 (20.16) 68.85
Borg Dyspnea
Scale
6.1 (2.33) 5.77 (2.12) 5.96
SGRQ 71.5 (15.97) 68.65 (16.32) 70.07
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Protocol steps
Screening: assessment of COPD diagnosis and assess-
ment of inclusion/exclusion criteria, prescription of a
wash out period (Ultra-LABA 72 h, LABA and LAMA
48 h, SABA 8 h).
Visit 1 (T0): the patients filled in a questionnaire, per-
formed lung function assessment, and oscillometry.
Then they were randomized in a 1:1 ratio to receive
either once daily IND/GLY 110/50 μg delivered via the
Breezhaler® device (Novartis Pharma AG, Basel,
Switzerland) or once- daily Tiotropium 2,5 μg Respimat®
device (Boehringer Ingelheim, Ingelheim, Germany). The
modality of drug taking was showed to patients and they
assumed it. After 1 h and 3 h from that time lung func-
tion and oscillometry were performed again.
Visit 2 (3 months +/− 1 week), 3 (6 months +/−
1 week), 4 (12 months +/− 1 week): the patients filled in
the questionnaire, repeated lung function assessment
and oscillometry before the intake of daily dose of drug.
They assumed the drug and performed again lung func-
tion assessment and oscillometry after 1 h and 3 h from
the drug intake.
At each of the 4 study visits the patients under-
took baseline tests (IOS, and spirometry), before
inhalation therapy, after 1 h and 3 h from inhalation.
Additional assessments were performed including the
exacerbation analysis, and quality of life score by
SGRQ.
Participants attended the department on the same
time during each study visit.
Impulse oscillometry
The IOS system (IOS, Jaeger Master Screen, Jaeger
Co, Wurzburg, Germany) noninvasively assesses re-
spiratory mechanics without patient cooperation using
small pressure oscillations generated at the mouth
during spontaneous breathing. During the test, sub-
jects firmly supported their cheeks while sitting with
their neck in a comfortable neutral posture, wearing a
nose clip, and tightly sealed their lips around the
mouthpiece in order to stabilize the position of their
tongue and to avoid buccal air leaks. Whole-breath,
inspiratory (insp), and expiratory (exp) IOS measures
of resistance measured the total airway resistance at
an oscillation frequency of 5 Hz (R5), central airway
resistance at 20 Hz (R20), peripheral resistance fre-
quency dependence of resistance from 5 to 20 Hz
(R5-R20), reactance at 5 Hz (X5), and area under the
reactance curve (AX) and the resonant frequency
(RF). Reported results are the average of 3 technically
acceptable periods of 40 to 60 s of measure. Impulse
oscillometry was performed in triplicate according to
the manufacturer’s instructions [11–13].
Spirometry
Lung function measurements were performed according
to manufacturer’s instructions and European Respiratory
Society (ERS)/American Thoracic Society (ATS) recom-
mendations [14, 15]. The reference values used were
established by Crapo et al. [16].
The FEV1, FVC and the Inspiratory Capacity (IC),
were measured using a dry wedge spirometer (Jaeger Co,
Wurzburg, Germany). Baseline values at each visit were
measured after at least 15 min of quiet rest, and the
results (absolute values and percent predicted) were
evaluated. Readings were again performed in triplicate,
with the highest FEV1 recorded.
Exacerbations
A COPD exacerbation is defined as an acute worsening
of respiratory symptoms which needs additional therapy,
regardless the factors that cause it [17].
Quality of life
St. George’s Respiratory Questionnaire (SGRQ) is a
disease-specific questionnaire designed to measure
HRQoL in patients with chronic lung diseases. It consists
of 17 questions divided into three categories: symptoms
(wheeze, cough, and dyspnea), activities that are limited
by the disease, and impact on the respondent’s social life
and mental state. The scores ranges from 0 to 100, and
lower values indicate better health status [18].
Data analysis
The study was powered at 90% to detect a 0.1 kPa L-1 s
difference in the primary outcome of trough R5, assuming
a within subject standard deviation of 0.13 kPa L-1 s, and
an alpha error of 0.05 (two-tailed) [19]. Students t-tests
were used to compare treatment effects at baseline and
after chronic dosing. The level of significance set at 0.05.
Exacerbations’ analysis on Relative Risk assessment was
based.
Results
Patients
Thirty-five patients completed the study (20 in Ind/Gly
group and 15 in Tio group). Mean age was 71.03 years.
Oscillometry
In Table 2 we compared pre dual bronchodilation values
at V1 and V4.
We found a significant difference between pre-dosing
R5Hz value at V1 and at follow up visits in patients
receiving dual bronchodilation (mean difference − 0.16,
95% CI -0.2829 to −0.0371, p = 0.0122) but not in
control group (mean difference − 0.07, 95% CI -0.2332
to 0.0984, p = 0.4111). R20Hz had a similar change
(mean difference − 0.066, 95% CI -0.1255 to −0.0061,
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p = 0.0318). Reactance (X) also showed a difference at
follow up only in patients receiving dual bronchodilation
(mean difference 0.146, 95% CI 0.0586 to 0.2340,
p = 0.0017) (Figs. 1 and 2).
Spirometry
Lung function was investigated pre and after 1 h and
3 h from the assumption of inhaled therapy. At each
visit we found that pre-dosing IC value in patients re-
ceiving dual bronchodilation had a statistical signifi-
cant variation (mean difference + 0.41L, 95% CI
0.0505 to 0.7695, p = <0.05). Other parameters did
not change neither after dual nor after mono-
bronchodilation, FEV1 did not change significantly in
cases (+0.12 L, p = 0.38), and in controls (−0.6 L,
p = 0.76). FVC did not change significantly in cases
(+0.0025 L, p = 0.99), and in controls (+0.01 L,
p = 0.92) (Figs. 3, 4, and 5).
Exacerbation rate
In patients receiving dual bronchodilation, we found a
reduction of 66% of exacerbations (RR = 0,3383 (95% CI
0.1722 to 0.6649, p = 0.0017). Hospitalization rate was
not different between the 2 groups, but among patients
receiving mono-therapy there were more frequent
exacerbators.
Health status
Comparing V1and V4 SGRQ, we found a mean differ-
ence of −13.25 points (95% CI 3.024 to 23.4758,
p = 0.0125) after dual bronchodilation therapy (Fig. 6).
Discussion
In this study, the efficacy of a maintenance combination
therapy with indacaterol/glycopyrronium versus tiotro-
pium on IOS parameters in patients with moderate to
severe COPD was studied. We demonstrated the efficacy
of the combination of IND/GLY versus tiotropium on
airway resistance (R5, R20, R5–20), lung reactance (X)
and resonant frequency. All of them are small airways
parameters. We don’t find a FEV1 and FVC statistical
significance for the small sample size but in many other
studies the once-daily fixed-dose combination IND/GLY
110/50 μg has been shown to significantly improve lung
function and patient-reported outcomes (including
dyspnea and health status) versus placebo, and versus
Tiotropium [20, 21].
In the SPARK study, Wedzicha et al. [22] demonstrated
that the dual bronchodilator IND/GLY was superior in
preventing mild to severe COPD exacerbations compared
with the single long-acting antimuscarinic bronchodilator
glycopyrronium, with concomitant improvements in lung
function and health status. Subsequently, the SHINE study
[23] confirmed that dual bronchodilation with QVA149
provides additional therapeutic benefits compared to the
mono-components indacaterol and glycopyrronium, as
well as compared to tiotropium, the current gold standard
of care, and placebo in patients with moderate-to-severe
COPD. The authors demonstrated that improvement in
the primary end-point, trough FEV1 was both statistically
and clinically significant (considered to be 100 mL in
COPD) over placebo and statistically significant versus
Table 2 Pre dual bronchodilation values at V1 and V4
V1 Pre dual bronchodilation V4 Pre dual bronchodilation
R 5 Hz 0.74 ± 0.23 0.58 ± 0.13
R 20 Hz 0.45 ± 0.10 0.38 ± 0.06
X 5 Hz -0.35 ± 0.16 -0.20 ± 0.09
IC 1.63 ± 0.59 2.04 ± 0.57
SGRQ 71.5 ± 15.97 58.25 ± 15.98
Fig. 1 Resistance and reactance before and after dual bronchodilation
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active comparators approaching also clinical significance.
IND/GLY also significantly improved TDI total scores
compared with tiotropium [21–23].
It is generally accepted that FEV1 is not an optimal
parameter for describing the complexity of COPD and
that other lung function assessments are necessary to
describe the disease pattern [24, 25].
Crisafulli et al. in an observational study on stable
COPD patients demonstrated that there is a progressive
increase in peripheral airway dysfunction among patients
with different GOLD stages evaluated by both GOLD
staging systems [25]. Furthermore, we demonstrated a
strong relationship between small-airway dysfunction
(SAD) as assessed by means of IOS and impact of dis-
ease [5].
Su-Gang Gong et al. observed that the IOS technology-
related parameters have high sensitivity in detecting the
slightly increased airway resistance that reflects a small
airway airflow limitation [26, 27].
Kolsum U et al. evaluated 94 COPD and 58 out of them
were followed up after 1 year . The authors confirmed that
IOS measurements are related to the degree of airflow ob-
struction as measured by forced expiratory volume in 1 s
(FEV1), and to the degree of hyperinflation. In addition, he
found R5, X5 were all significantly associated (p < 0.05)
with FEV1, sGaw, TLC, RV and IC but there was no statisti-
cally significant change in the FEV1, R5, X5 after 1 year. For
the authors the changes in R5 and R20 did not significantly
correlate with the changes in FEV1 [28].
It is known that bronchodilators increase airway diam-
eters and decrease airway resistance making the pattern
of airway obstruction more homogeneous in COPD pa-
tients [1]. The airway’s parameters of spirometry and the
IOS are considered in the assessment of physiological
changes in the large and small airways separately.
Among these spirometric parameters, FEV1 is not well
suited to assess the abnormalities in the small airways
and is characterized as a large-airway parameter.
Fig. 2 Resistance and reactance before and after tiotropium
Fig. 3 Pre-dosing Fev1(liters and DS) in two groups at T0 and after 52 weeks
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Raw is not frequently reported in studies evaluating
the effect of bronchodilators in COPD. However, this
parameter is suggested to be sensitive and to reflect
airflow obstruction, particularly of the peripheral
airways, more accurately than the FEV1/FVC ratio
[29]. In assessing the acute functional effect of bron-
chodilators, specific Raw change-based criteria may be
preferable to FEV1- or FVC-based criteria, being more
closely related to bronchodilator-induced improve-
ments in lung mechanics and dyspnea at rest.
Other parameters such as R10 and AX have also
been shown to change in response to the bronchodi-
lators [30, 31].
Manoharan et al., in randomized patients with moderate
to severe COPD already taking ICS/LABA to receive add-
on therapy in cross-over fashion with either TIO 18 μg od
or ACL 322 μg subsequently bid for 2–3 weeks each, ob-
served no significant differences between randomized
treatments in any IOS or spirometry outcomes measured
at trough after chronic dosing with TIO and ACL when
used as triple therapy in patients with COPD [20].
In our study also the IC, the best parameter related
to the reduction of hyperinflation [32], in patients re-
ceiving dual bronchodilation was improved. Improved
IC is associated with improved exercise endurance and
dyspnea [33, 34] and potentially improved long-term
outcomes. Furthermore, the improvement in measures
of hyperinflation is supported by the BRIGHT study
[35] and recently by Salomon et al. [36].
Conclusion
The oscillometry demonstrated greater sensitivity com-
pared with spirometry for monitoring outcome measures
of airway obstruction and the effect of long term therapy.
This technique should facilitate the early optimization of
therapy and a more personalized therapeutic approach for
COPD patients. These data support the use of dual
Fig. 4 Pre-dosing FVC (liters and DS) in two groups at T0 and after 52 weeks
Fig. 5 Pre-dosing IC in two groups at T0 and after 52 weeks
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bronchodilator therapy to not only improve airways
calibre (FEV1) but also decrease hyperinflation and its as-
sociated negative consequences in patients with COPD.
On the small airways, the combination IND/GLY in-
duces a decrease of dynamic compression, a consequent
decrease of dynamic hyperinflation leading to less dyspnea
during exercise.
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